SGCE missense mutations that cause myoclonus-dystonia syndrome impair epsilon-sarcoglycan trafficking to the plasma membrane: modulation by ubiquitination and torsinA by Esapa, Christopher T. et al.
SGCE missense mutations that cause
myoclonus-dystonia syndrome impair
1-sarcoglycan trafficking to the plasma membrane:
modulation by ubiquitination and torsinA
Christopher T. Esapa1,{, Adrian Waite1,{, Matthew Locke1, Matthew A. Benson1,
Michaela Kraus3, R.A. Jeffrey McIlhinney2, Roy V. Sillitoe1,{, Philip W. Beesley3
and Derek J. Blake1,*
1Department of Pharmacology, 2Medical Research Council Anatomical Neuropharmacology Unit, University of
Oxford, Mansfield Road, Oxford OX1 3QT, UK and 3School of Biological Sciences, Royal Holloway, University of
London, Egham, Surrey TW20 0EX, UK
Received November 13, 2006; Revised and Accepted December 15, 2006
Myoclonus-dystonia syndrome (MDS) is a genetically heterogeneous disorder characterized by myoclonic
jerks often seen in combination with dystonia and psychiatric co-morbidities and epilepsy. Mutations in
the gene encoding 1-sarcoglycan (SGCE) have been found in some patients with MDS. SGCE is a maternally
imprinted gene with the disease being inherited in an autosomal dominant pattern with reduced penetrance
upon maternal transmission. In the central nervous system, 1-sarcoglycan is widely expressed in neurons of
the cerebral cortex, basal ganglia, hippocampus, cerebellum and the olfactory bulb. 1-Sarcoglycan is located
at the plasma membrane in neurons, muscle and transfected cells. To determine the effect of MDS-associated
mutations on the function of 1-sarcoglycan we examined the biosynthesis and trafficking of wild-type and
mutant proteins in cultured cells. In contrast to the wild-type protein, disease-associated 1-sarcoglycan mis-
sense mutations (H36P, H36R and L172R) produce proteins that are undetectable at the cell surface and are
retained intracellularly. These mutant proteins become polyubiquitinated and are rapidly degraded by the
proteasome. Furthermore, torsinA, that is mutated in DYT1 dystonia, a rare type of primary dystonia, binds
to and promotes the degradation of 1-sarcoglycan mutants when both proteins are co-expressed. These
data demonstrate that some MDS-associated mutations in SGCE impair trafficking of the mutant protein to
the plasma membrane and suggest a role for torsinA and the ubiquitin proteasome system in the recognition
and processing of misfolded 1-sarcoglycan.
INTRODUCTION
The sarcoglycans are a family of single pass transmembrane
proteins that are part of the dystrophin-associated glycoprotein
complex (DGC); a multiprotein complex that links the actin
cytoskeleton to the extracellular matrix in cardiac and skeletal
muscle (1). The DGC can be separated biochemically into
three smaller sub-complexes; the cytoplasmic sub-complex
that contains dystrophin, the dystrobrevins and the syntro-
phins, the dystroglycan sub-complex and the sarcoglycan:sar-
cospan sub-complex (2). Although the precise function of the
sarcoglycan sub-complex is not known, mutations in a-, b-,
g- and d-sarcoglycan cause different forms of autosomal
recessive limb girdle muscular dystrophies (LGMD) demon-
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strating its importance for normal muscle function. Based on
studies in heterologous cells, it is apparent that co-synthesis
of at least two different sarcoglycans is required for efficient
membrane targeting of the sarcoglycan complex (3,4). More-
over, disease-associated sarcoglycan mutations often affect the
assembly and trafficking of the entire sarcoglycan sub-
complex to the sarcolemma (5). In contrast to the other sarco-
glycans (a, b, g and d) which are expressed predominantly in
striated and smooth muscles, 1-sarcoglycan, a paralogue of
a-sarcoglycan, is expressed in a wide range of tissues with
the highest levels in heart and lung (6–9). 1-Sarcoglycan is
associated with the other sarcoglycans in C2C12 cells (10),
vascular smooth muscle (11) and peripheral nerves (12). In
the brain, 1-sarcoglycan is found in the midbrain monoaminer-
gic neurons, in cerebellar Purkinje cells and in other brain
regions including the hippocampus and cortex (6,8,13). In
contrast, very little is known about the core sarcoglycan
complex in the brain. Northern and western blot analysis
shows that a-, g- and d-sarcoglycan and sarcospan only
appear to be expressed in cardiac, skeletal and smooth
muscles (14). b-Sarcoglycan is expressed weakly in brain,
whereas the recently discovered z-sarcoglycan appears to be
more widely expressed (15,16). From these studies, it is appar-
ent that if a sarcoglycan complex exists in neurons it will
differ significantly from the complex found in muscle.
Mutations in the gene encoding 1-sarcoglycan (SGCE)
cause a form of dystonia called myoclonus-dystonia syndrome
(MDS, DYT11) (17–19). MDS is a rare dystonia plus syn-
drome characterized by early-onset myoclonus (shock-like
jerks) commonly associated with focal or segmental dystonia
and more infrequently, with psychiatric disturbances such as
panic attacks and obsessive compulsive disorder (20).
Inheritance of MDS is autosomal dominant and typically
involves the presence of bilateral myoclonus that affects the
arms, neck and trunk (21,22). Although MDS is genetically
heterogeneous, mutations in the SGCE gene appear to be a
significant cause of MDS in some populations. The SGCE
gene is maternally imprinted (paternally expressed) that
explains the reduced penetrance of MDS when the disease is
maternally transmitted (17,23). Importantly, the SGCE gene
is imprinted in both humans and mice such that only the
paternal allele is thought to be expressed in the brain and
other tissues in the periphery (17,23–25). Mutations associ-
ated with other hereditary forms of dystonia have also been
found in the genes encoding torsinA (early-onset torsion dys-
tonia, DYT1), GTP cyclohydrolase-1 (GCH1 formerly known
as DYT5) and the a3-subunit of the Naþ/Kþ-ATPase
(ATP1A3) (26).
While a multitude of studies have identified mutations in the
SGCE gene in patients with MDS (18,19,27–29), the conse-
quences of these mutations on the 1-sarcoglycan protein
have not been determined. The majority of SGCE mutations
reported in MDS families are nonsense mutations that would
abolish the synthesis of the full-length protein. Recently,
three missense mutations (H60R, H60P and L196R) in the
SGCE gene have been reported that could provide important
insights into the function of 1-sarcoglycan in the central
nervous system and the molecular pathology of MDS
(18,30). Here, we show that SGCE missense mutants reported
in patients with MDS produce proteins that are not trafficked
to the plasma membrane but are retained intracellularly,
ubiquitinated and degraded by the proteasome.
RESULTS
Location of endogenous 1-sarcoglycan
The esg-5009 antibody was used to determine the tissue distri-
bution of 1-sarcoglycan and its regional localization in the
brain. On western blots, esg-5009 detects a 50 kDa protein
in all tissues tested (Supplementary Material, Fig. S1). The
highest levels of 1-sarcoglycan are found in lung, heart and
spleen. In agreement with previous studies, 1-sarcoglycan is
resolved as a doublet in mouse brain (Supplementary Material,
Fig. S1) (6).
To determine the subcellular location of 1-sarcoglycan in
neurons and muscle, the esg-5009 antibody was used to
stain cultured hippocampal neurons and muscle sections. In
hippocampal neurons cultured for 21 days in vitro (21
d.i.v.), 1-sarcoglycan is found at the plasma membrane of den-
drites and the soma but is also concentrated in discrete cyto-
plasmic punctae and associated with the Golgi apparatus
(Supplementary Material, Fig. S2A). In normal muscle,
1-sarcoglycan is found at the muscle plasma membrane (sar-
colemma) and also in blood vessels and peripheral nerves
(Supplementary Material, Fig. S2B). In contrast to the other
members of the sarcoglycan family, 1-sarcoglycan is retained
at the sarcolemma of dystrophin-deficient mdx mouse muscle
albeit at reduced levels compared with the wild-type C57
control (Supplementary Material, Fig. S2B). These data
show that under physiological conditions, 1-sarcoglycan is
found at the plasma membrane in neurons and muscle and
within intracellular inclusions and the Golgi apparatus of
cultured hippocampal neurons.
Missense mutations are associated with intracellular
retention of the mutant protein
The majority of SGCE mutations that cause MDS are inser-
tions, deletions or nonsense mutations that result in premature
termination of the protein. Recently, three missense mutations,
H60P, H60R and L196R have been described that should
result in the synthesis of full length proteins carrying a
single altered amino acid (18,30). H60 is located within the
dystroglycan-type cadherin-like (CADG) domain of
1-sarcoglycan (31), while L196 is conserved in the vertebrate
orthologues of a- and 1-sarcoglycan. The mouse mutants,
H36P/R and L172R used in this study correspond to the
human 1-sarcoglycan mutations, H60P/R and L196R, respect-
ively. The three mutations modelled here affect amino acid
residues that are conserved between the human and mouse
orthologues. Thus, the mouse cDNA is an appropriate source
of 1-sarcoglycan for this study. Furthermore, mice with a tar-
geted deletion of Sgce exon 4 have myoclonus, motor impair-
ments, hyperactivity, anxiety, depression and some
neurochemical abnormalities (25,32). It is noteworthy that
the mouse sequence has a shorter predicted signal sequence
when compared with the human sequence, but following pro-
cessing each protein is predicted to start at the same amino
acid (VHS/DR). In order to determine the subcellular location
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of wild-type 1-sarcoglycan and the three mutants, constructs
encoding each protein were transfected into COS-7 cells and
stained with the esg-5009 antibody. As shown in Figure 1,
wild-type 1-sarcoglycan localizes to the plasma membrane
and some intracellular structures including the Golgi-
apparatus (co-localizing with the Golgi-matrix protein,
GM130) and post-Golgi vesicles. This distribution clearly
differs from the endoplasmic reticulum (ER) labelled with
an anti-protein disulphide isomerase (PDI) antibody. In con-
trast, each of the MDS-associated 1-sarcoglycan mutants
were mislocalized and retained intracellularly in the ER
(Fig. 1). The ER localization of H36P/R and L172R was con-
firmed by co-localization with PDI. The H36R mutant was
also found in punctae within the ER that could correspond
to the formation of small aggregates (Fig. 1). Both untagged
and enhanced yellow fluorescent protein (EYFP)-tagged con-
structs gave the same distribution pattern in transfected cells.
While many studies have been conducted on the function of
torsinA in heterologous cells (33,34), it is important to deter-
mine whether the MDS-associated mutants were mislocalized
in cell types with neuronal phenotypes. EYFP-tagged
constructs were transfected into cortical neurons (Fig. 2) and
SH-SY5Y neuroblastoma cells (Fig. 3). Each of these cell
types have been used to study the function and immuno-
localization of torsinA (35,36). In cultured cortical neurons,
wild-type 1-sarcoglycan is found throughout the dendrites
and soma where it partially co-localizes with GM130
(Fig. 2). Discrete punctae, reminiscent of transport vesicles,
are visible within the diffuse staining in both dendrites and
soma. These punctae do not co-localize with GM130 or PDI.
In contrast, the mutants H36P and H36R are diffusely distrib-
uted within the soma and proximal dendrites of cortical
neurons co-localizing with PDI (Fig. 2). There is no evidence
that either mutant forms punctae in distal parts of the cell.
L172R-YFP forms discrete punctae in the soma and proximal
dendrites of cortical neurons (Fig. 2). These punctae
co-localize precisely with PDI in cells expressing the L172R
mutant. L172R-YFP does not co-localize with GM130. Thus,
it appears that in neurons, L172R can form ER-associated
aggregates. Each MDS-associated 1-sarcoglycan mutant is
therefore mislocalized in cortical neurons. Finally, we exam-
ined the distribution of 1-sarcoglycan and the MDS-associated
Figure 1. Intracellular retention of 1-sarcoglycan mutants in COS-7 cells. Cells expressing wild-type 1-sarcoglycan or 1-SG-H36P, 1-SG-H36R and 1-SG-L172R
were counterstained with anti-GM130 (Golgi apparatus) or anti-PDI (ER) antibodies. Wild-type 1-sarcoglycan is targeted to the plasma membrane (large arrow-
head) but is also found in intracellular compartments including the Golgi apparatus (small arrowhead). The MDS-associated mutants are found ostensibly in
intracellular compartments, notably the ER, where they co-localize in part with PDI. The H36R mutant is also found in the Golgi apparatus and as small
punctae within the ER. For each mutant there is no evidence of plasma membrane labelling. Scale bar, 20 mm.
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mutants in SH-SY5Y cells (Fig. 3). The wild-type protein is
detected at the plasma membrane of neuroblastoma cells but
is also found in the Golgi apparatus, co-localizing with
GM130 and within vesicular structures (Fig. 3). Each of the
MDS-associated mutants is mislocalized in SH-SY5Y cells
and are found within the ER partially co-localizing with
PDI. The H36R mutant can form perinuclear punctae reminis-
cent of ER-associated aggregation (Fig. 3). Thus, each
MDS-associated 1-sarcoglycan mutant is mislocalized in
SH-SY5Y cells.
1-Sarcoglycan mutants are degraded by the proteasome
Proteins in the secretory pathway are scrutinized by an elabor-
ate quality control system in the ER such that misfolded pro-
teins are retrotranslocated from the ER and degraded in the
cytoplasm by the proteasome. The intracellular retention of
the H36R/P and L172R mutants suggested that the proteins
were possibly misfolded and therefore could be authentic
substrates for the proteasome. 1-Sarcoglycan is a type 1 trans-
membrane protein whose N-terminus has a single conserved
consensus site, NIT (amino acids 176–178), for N-linked gly-
cosylation. Thus the presence of N-linked glycans on
1-sarcoglycan and the mutants would indicate that each
protein had entered the ER lumen. Accordingly, both wild-
type 1-sarcoglycan and the MDS-associated mutants H36P/R
and L172R are glycosylated in HEK 293T cells (Fig. 4A).
Each protein is sensitive to the glycosidases Endo H and
PNGase F, indicating that 1-sarcoglycan and the
MD-associated mutants possess high mannose structures
(Fig. 4A). Furthermore, this pattern of glycosidase sensitivity
is also found in 1-sarcoglycan purified from mouse brain indi-
cating that HEK 293T cells process and traffic 1-sarcoglycan
in a similar manner to brain (Fig. 4B). Treatment with each
glycosidase reduces the apparent relative molecular mass of
1-sarcoglycan by 2 kDa. As described previously for
b-dystroglycan, a reduction of 2 kDa corresponds to the occu-
pancy of a high mannose glycan at a single sequon (37). These
Figure 2. Mislocalization of YFP-tagged 1-sarcoglycan mutants in cortical neurons. Cells expressing EYFP-tagged wild-type 1-sarcoglycan or 1-SG-H36P,
1-SG-H36R and 1-SG-L172R were counterstained with anti-GM130 or anti-PDI antibodies. YFP-tagged, wild-type 1-sarcoglycan is found in the soma and den-
drites of neurons and co-localizes in part with GM130. PDI was distributed diffusely in the soma and dendrites of neurons. Among the diffuse labelling, pro-
minent punctae are visible both within the soma and in most dendrites. These punctae did not co-localize with PDI. In contrast to the wild-type protein,
1-SG-H36R and 1-SG-H36P were localized diffusely in the soma and dendrites of neurons. These mutants co-localized with PDI but failed to co-localize
with the GM130. The L172R mutant formed discreet punctae within the neuronal soma and proximal dendrite. These punctae did not co-localize with
GM130 but did co-localize perfectly with PDI that appeared to be redistributed into punctae within the neuronal soma and proximal dendrite. The nuclear
membrane (arrowhead) is visible in cells expressing ER-retained mutants. Scale bar, 20 mm.
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data demonstrate that 1-sarcoglycan and the three missense
mutants can enter the ER.
Quantitative western blot analysis of the MDS-associated
mutants showed that the steady-state expression levels of the
mutants H36P, H36R and L172 were consistently lower than
the wild-type protein. If an arbitrary level of 100+ 4.0%
(SEM) is assigned to wild-type 1-sarcoglycan, the relative
levels of each MDS-associated mutant are as follows; H36P,
25.4+ 6.9%, H36R, 26.1+ 0.6% and L172R, 85+ 3.0%.
To determine whether the observed reduction in the levels
of the 1-sarcoglycan mutants was due to proteasome-mediated
degradation, HEK 293T cells were transfected with either
wild-type 1-sarcoglycan or the MDS-associated mutants and
HA-tagged ubiquitin (a kind gift from Prof. Dirk Bohmann)
in the presence and absence of the proteasome inhibitor lacta-
cystin (Fig. 4C). Ubiquitination was assessed by immunopre-
cipitation of 1-sarcoglycan and the mutants from transfected
cells followed by western blotting of the immunoprecipitates
with the anti-HA and esg-5009 antibodies. The highest
levels of polyubiquitinated 1-sarcoglycan were detected in
immunoprecipitates from cells expressing the H36P/R
mutants and to a lesser extent the L172R mutant
when incubated with lactacystin (Fig. 4C, upper panel).
Polyubiquitinated H36P-1-sarcoglycan could also be detected
in the absence of lactacystin (Fig. 4C, upper panel).
Polyubiquitinated wild-type 1-sarcoglycan can also be
detected with the proteasome inhibitor suggesting that a pro-
portion of this protein may be destroyed by the proteasome.
The presence of polyubiquitinated 1-sarcoglycan was also
detected with the esg-5009 antibody (Fig. 4C, middle panel).
To determine the effect of MDS-associated mutations on the
stability of 1-sarcoglycan, quantitative western blots were
used to determine the half-lives of each protein in the presence
and absence of the proteasome inhibitor MG132 (Fig. 5). In
these experiments, protein synthesis was inhibited with cyclo-
heximide and 1-sarcoglycan levels were normalized to
endogenous a-tubulin on the same blot using two-colour
imaging. MG132 was used in preference to lactacystin
because we found that lactacystin combined with cyclohexi-
mide was toxic to transfected HEK 293T cells. Under these
conditions, wild-type 1-sarcoglycan had a half-life of 5.0 h
that increases to 7.8 h with the addition of MG132. Similarly,
Figure 3. Mislocalization of YFP-tagged 1-sarcoglycan mutants in SH-SY5Y neuroblastoma cells. Cells expressing EYFP-tagged wild-type 1-sarcoglycan or
1-SG-H36P, 1-SG-H36R and 1-SG-L172R were counterstained with anti-GM130 or anti-PDI antibodies. Wild-type 1-sarcoglycan is targeted to the plasma mem-
brane but is also found in intracellular compartments including the Golgi apparatus and small vesicular structures. The tagged MDS-associated mutants are not
targeted to the plasma membrane but are retained in the ER where they co-localize in part with PDI. In SH-SY5Y cells, the H36R mutant is also found within
small perinuclear vesicular structures. The nuclear membrane (arrowhead) is prominent in cells expressing ER-retained mutants. Scale bar, 20 mm.
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Figure 4. Polyubiquitination of MDS-associated 1-sarcoglycan mutants. (A) Western blot using anti-esg 5009 antibody showing that 1-sarcoglycan, H36P/R and
L172R are glycoproteins and have therefore entered the ER. Proteins prepared from transfected HEK 293T cells expressing the indicated constructs were
digested with Endo H and PNGase F. In each case glycosidase treatment reduced the apparent relative molecular mass of each protein by 2 kDa. (B) Glyco-
sidase sensitivity of brain-derived 1-sarcoglycan. 1-Sarcoglycan was immunoprecipitated from mouse brain and treated as indicated. Endo H and PNGase F
reduced the apparent relative molecular mass of each protein by 2 kDa. Brain-derived 1-sarcoglycan exists as a dimer due to alternative splicing of the
C-terminus [see Supplementary Material, Fig. S1 and (6)]. (C) Ubiquitination of 1-sarcoglycan. 1-Sarcoglycan was immunoprecipitated from HEK 293T
cells expressing the constructs as indicated. The upper panel shows that the anti-HA antibody detects polyubiquitinated 1-sarcoglycan in the presence of lacta-
cystin (þ) and even when the drug was omitted (2) in the case of the H36P/R mutants. The presence of 1-sarcoglycan in each immunoprecipitation (middle
panel) and the cell lysates (lower panel) are shown for comparison. Note that polyubiquitinated 1-sarcoglycan is also detected with the esg-5009 antibody
(middle panel).
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the half-life of the L172R mutant is 4.2 h in untreated cells but
increases to 7.6 h after proteasome inhibition. The H36P and
H36R mutants that are expressed at lower levels and heavily
polyubiquitinated relative to the wild-type protein and the
L172R mutant (Fig. 5) had half-lives ,2.0 h. Incubation of
H36P and H36R with MG132 increased the half-lives of the
protein to 4.6 h and 4.8 h, respectively.
Impaired plasma membrane targeting of mutant
1-sarcoglycan
To demonstrate that intracellular retention of the mutated pro-
teins and preferential degradation by the proteasome affected
plasma membrane delivery, cell surface biotinylation was
used to establish whether each protein was trafficked to the
surface of transfected HEK 293T cells. These experiments
were performed in the presence and absence of the proteasome
inhibitor lactacystin. Wild-type 1-sarcoglycan is targeted to
the plasma membrane in the absence of lactacystin, while
incubation with lactacystin increased the levels of the
protein at the cell surface (Fig. 6A). In contrast, no surface-
expressed protein could be detected with any of the
MDS-associated mutants that were expressed under the same
conditions and even in the presence of lactacystin (Fig. 6A).
Control experiments showed that 1-sarcoglycan was efficiently
immunoprecipitated in each case and that incubation with lac-
tacystin dramatically increased the levels of the H36P mutant
(and to a lesser extent wild-type 1-sarcoglycan and the L172R
and H36R mutants) in both the immunoprecipitates and cell
lysates (Fig. 6A). Immunoblotting with an anti-a-tubulin anti-
body showed that each transfection contained similar levels of
a protein that was unaltered by incubation with lactacystin
(Fig. 6A). These data support our hypothesis that some
1-sarcoglycan mutations produce proteins that have impaired
intracellular transport and cannot reach the plasma membrane.
Thus, 1-sarcoglycan can be efficiently trafficked to the cell
surface without co-synthesis of the other sarcoglycans (4).
While the esg-5009 detects human 1-sarcoglycan in brain
extracts (Supplementary Material, Fig. S3A), endogenous
1-sarcoglycan was not detected in COS-7 or HEK 293T cells
(Supplementary Material, Fig. S3A and Fig. 3B). This is in
agreement with previous studies that failed to detect endogen-
ous sarcoglycans in heterologous cell lines including HEK
293 and COS-1 (38,39). Furthermore, we were unable to
detect a- and b-sarcoglycan in COS-7 cells, suggesting that
the plasma membrane trafficking of 1-sarcoglycan in this cell
type is not dependent upon the presence of the other sarcogly-
cans (Supplementary Material, Fig. S3B). To determine
whether other components of the DGC were in a complex
with 1-sarcoglycan, we immunoprecipitated 1-sarcoglycan
from mouse brain extracts prepared in RIPA buffer (Sup-
plementary Material, Fig. S4). While 1-sarcoglycan was
highly enriched in these preparations, components of the core
DGC such as dystrophin, Dp71, the dystrobrevins and
b-dystroglycan were not co-purified. These data suggest that
in the brain, 1-sarcoglycan may not be a component of the
DGC-like complexes found in neurons (40).
It has previously been shown that mutations in one member of
the sarcoglycan sub-complex can affect the trafficking of the
other components to the plasma membrane (3–5). Since
SGCE is a maternally imprinted (paternally expressed) gene,
the expression of 1-sarcoglycan will be monoallelic if the
locus is faithfully imprinted. The vast majority of MDS patients
only express a single mutant allele suggesting that loss of func-
tion may be the underlying cause of the disease. However, there
are cases in the literature where imprinting has been lost and the
individuals with MDS are thought to express both a untagged
and mutant SGCE allele (23). Given that mutations in the
gene encoding 1-sarcoglycan cause MDS that is inherited in
an autosomal dominant manner we sought to determine
whether the 1-sarcoglycan mutants could behave in a dominant-
negative manner by impairing trafficking of the wild-type
protein to the cell plasma membrane. To investigate a dominant-
negative effect on 1-sarcoglycan trafficking to the cell surface,
wild-type 1-sarcoglycan and the mutants H36P and L172R
were co-expressed with 1-sarcoglycan:EYFP that, like the wild-
type protein, is normally trafficked efficiently to the cell surface.
The 1-sarcoglycan:EYFP chimera has a higher relative molecu-
lar mass when compared with the untagged protein that can be
easily resolved by SDS–PAGE (Fig. 6B). The same experimen-
tal paradigm was applied as described above except that the
wild-type and mutant 1-sarcoglycans were co-transfected with
1-sarcoglycan:EYFP. Surface biotinylation of proteins expressed
in cells co-transfected as shown in Figure 6B showed that com-
parable levels of 1-sarcoglycan:EYFP are present at the plasma
membrane in each transfection. In cells expressing untagged
1-sarcoglycan and 1-sarcoglycan:EYFP, both proteins can be
readily detected at the surface by biotinylation (Fig. 6B).
When 1-sarcoglycan:EYFP is co-expressed with the untagged
mutants, low levels of the mutant become biotinylated indicating
that, under these conditions, they can be trafficked to the plasma
membrane. Thus the wild-type protein may promote the traffick-
ing of the mutant protein to the membrane as part of a homo-
typic protein complex. These data show that MDS-associated
Figure 5. MDS-associated 1-sarcoglycan mutants have shorter half-lives.
Graphical representation of the protein levels of wild-type 1-sarcoglycan,
H36P/R and L172R over time. The protein levels of wild-type 1-sarcoglycan,
H36P/R and L172R were normalized to a-tubulin following the addition of
cycloheximide (0 h) in the presence or absence of the proteasome inhibitor,
MG132. The inset shows a representative, quantitative immunoblot of H36P
(red) and a-tubulin (green) with and without MG132. The error bars show
the SEM from four to six independent experiments.
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mutants do not behave in a dominant-negative manner to impair
plasma membrane delivery of the wild-type protein (Fig. 6B).
Intracellular mobility of 1-sarcoglycan and mutants
Fluorescence recovery after photobleaching (FRAP) was used
to determine the mobility of the wild-type and mutant
1-sarcoglycans in the ER (Fig. 7A). It has been demonstrated
that some misfolded membrane proteins have altered rates of
diffusional mobility associated with the formation of mixed
disulphide bonds with ER-resident chaperones when ATP is
depleted (41). EYFP-tagged constructs were transfected into
COS-7 cells and used to measure FRAP rates in cells incu-
bated with brefeldin A to block protein transport in the
secretory pathway. In cells expressing the wild-type protein,
no significant difference in FRAP rates was found when
Figure 6. 1-Sarcoglycan mutants are poorly targeted to the plasma membrane. (A) Twenty-four hours after transfection, HEK 293T cells expressing the desig-
nated constructs were treated with lactacystin (þ) or left untreated (2) and incubated for a further 18 h. Following cell surface biotinylation, 1-sarcoglycan
proteins were immunoprecipitated with the esg-5009 antibody cross-linked to protein G-Sepharose beads. The streptavidin–horseradish peroxidase (HRP)
blot detects biotinylated protein and shows that 1-sarcoglycan is found at the cell surface. Furthermore, the levels of 1-sarcoglycan at the cell surface are
increased by proteasome inhibition. No cell surface labelling of the MDS-associated mutants could be detected even when the cells were pre-treated with lacta-
cystin. The lysates were blotted with the anti-a-tubulin antibody to show equal amounts of protein. (B) MDS-associated mutants do not have a dominant-negative
effect on the trafficking of the wild-type protein. Cell surface biotinylation of HEK 293T cells expressing 1-sarcoglycan:EYFP with wild-type and
MDS-associated 1-sarcoglycan mutants as indicated. Tagged (EYFP) and untagged 1-sarcoglycan was immunoprecipitated using the esg-5009 antibody. The
upper panel shows that the levels of 1-sarcoglycan:EYFP at the plasma membrane remain similar even in the presence of the MDS-associated mutants. The
middle panel shows the levels of 1-sarcoglycan in the immunoprecipitates, while the lower panel shows the presence of each of the proteins in the lysates.
As described previously, the H36R mutant is rapidly degraded by the cell and therefore present at reduced levels when compared with the other proteins.
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ATP was depleted with 2-deoxyglucose (Fig. 7A). Cells
expressing L172R showed a significant reduction in FRAP
times upon ATP-depletion when compared with the wild-type
control (Fig. 7A). Interestingly, the H36P mutant behaved
similarly to the wild-type protein when ATP was depleted
suggesting that ER-retention of this protein was not dependent
on disulphide bond formation (Fig. 7A).
Biochemical techniques were used to confirm the findings
of the FRAP studies as follows. The N-terminus of
1-sarcoglycan has two pairs of cysteine residues that could
Figure 7.MDS-associated mutations affect protein dynamics. (A) FRAP analysis of 1-sarcoglycan and MDS-associated mutants. Living COS-7 cells expressing
EYFP-tagged constructs were photobleached with high intensity laser light. The recovery of the bleached area was monitored for several minutes to examine the
rate of fluorescence recovery. The FRAP recovery curves for wild-type 1-sarcoglycan, H36P and L172R are shown as indicated. The experiments were per-
formed under two conditions: (i) in normal HBSS containing 1 mM glucose or (ii) in HBSS without glucose and containing 2-deoxyglucose and sodium
azide to deplete ATP (ATP depleted). The error bars show the SEM on data obtained from at least 10 independent cells. (B) Biochemical detection of high
molecular weight 1-sarcoglycan aggregates. Proteins were extracted from cells expressing the indicated constructs and separated under native and reduced
PAGE conditions. In addition to the prominent 50 kDa 1-sarcoglycan monomer, the mutants H36P and L172R show high molecular weight adducts that are
removed by pre-incubation with 5% 2-mercaptoethanol. The thiol-selective cross-linker BMH is also able to cross-link the MDS-associated mutants into non-
reducible high molecular weight aggregates similar to those detected by native PAGE.
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form disulphide bonds in the native protein. An additional
cysteine close to the N-terminus of 1-sarcoglycan is located
within the signal peptide and is therefore unlikely to be
present in the mature protein. The formation of mixed disul-
phide bonds that retain proteins in the ER was demonstrated
using native polyacrylamide gel electrophoresis (PAGE) and
cross-linkers. Figure 7B shows that a proportion of the
L172R, and to a lesser extent H36P/R forms high molecular
weight aggregates on native PAGE that are absent when the
protein is reduced with 2-mercaptoethanol. In contrast, wild-
type 1-sarcoglycan is essentially resolved as a single correctly
folded protein on both native and reducing polyacrylamide
gels. The susceptibility of the protein to the thiol-reactive
cross-linker bismaleimidohexane (BMH) was also used to
show the presence of free thiols in the mutants. BMH is
able to oxidatively cross-link free thiol groups to form a
stable thioether linkage. When the cell lysates are treated
with BMH, the mutants L172R and H36P are associated
with high molecular weight, cross-linked adducts while the
wild-type protein is unmodified (Fig. 7B). Importantly, the
BMH cross-linked proteins are resistant to chemical reduction
and can be separated by reduced PAGE (Fig. 7B). The diffuse
pattern of high molecular weight aggregates is consistent with
our hypothesis that the MDS-associated 1-sarcoglycan
mutants co-associate with intracellular chaperones rather
than forming homotypical aggregates.
Interaction with torsinA and effect on 1-sarcoglycan
trafficking and steady-state levels
Although each of the 1-sarcoglycan mutants are retained intra-
cellularly and degraded by the proteasome, there are several
important differences between the behaviour of the L172R
mutant compared with the H36P/R mutants. These differences
in behaviour prompted us to look for a potential interaction
between 1-sarcoglycan and torsinA because the L172R
mutation was found in association with a torsinA mutation
(42). To determine whether 1-sarcoglycan and torsinA inter-
act, we co-expressed the wild-type protein and H36P, H36R
and L172R mutants with wild-type and mutant torsinA. The
mouse torsinA mutant, torsinADE304, used in this study
corresponds to the common mutation DE302/303(Dgag)
described in DYT1 patients (43). TorsinA and torsinADE304
co-immunoprecipitated with the 1-sarcoglycan mutants when
co-expressed in HEK 293T cells (Fig. 8A). Very little wild-
type 1-sarcoglycan is found in the torsinA immunoprecipi-
tates, however, this does not negate the possibility that the
wild-type proteins bind transiently in the ER, a common
finding with chaperone–substrate interactions. Furthermore,
1-sarcoglycan and torsinA could not be immunoprecipitated
from mouse brain extracts. This is not surprising because we
have shown that torsinA preferentially binds misfolded con-
formations of 1-sarcoglycan (Fig. 8A). In control experiments
we examined the potential association between torsinA,
a-sarcoglycan and the ER-retained mutant, H77C-a-sarcogly-
can (44) (Supplementary Material, Fig. S5). TorsinA could
not be co-immunoprecipitated with either EYFP-tagged
a-sarcoglycan construct and had no apparent affect upon the
steady-state levels of each protein when co-expressed in heter-
ologous cells (Supplementary Material, Fig. S5).
Figure 8. Interaction of 1-sarcoglycan mutants with torsinA. (A) HEK 293T
cells were transfected as indicated. Western blot analysis of
co-immunoprecipitated proteins reveals that the 1-sarcoglycan mutants,
H36P and L172R are associated with torsinA and torsinADE304 (middle
panel). TorsinA is expressed uniformly and immunoprecitated in each trans-
fection (upper panel) however, as described previously, the H36P mutant is
poorly expressed (lower panel). (B) Effect of torsinA on the cell surface target-
ing of 1-sarcoglycan and MDS-associated mutants. The presence of
1-sarcoglycan at the plasma membrane of HEK 293T cells co-expressing
the indicated constructs was determined by cell surface biotinylation on non-
permeabilized cells. TorsinA and torsinADE304 have no apparent effect on the
surface expression of 1-sarcoglycan. Furthermore, torsinA was unable to
restore surface expression of H36P and L172R. TorsinA co-expression dra-
matically reduces the steady-state levels of the MDS-associated 1-sarcoglycan
mutants (middle panels). Quantitation of 1-sarcoglycan levels in cells
co-expressing torsinA. (C) The steady-state levels of 1-sarcoglycan and
a-tubulin were determined in COS-7 cells expressing the indicated constructs
(wild-type 1-sarcoglycan and mutants co-transfected with pCIneo or torsinA-
myc). The levels of 1-sarcoglycan were normalized to a-tubulin and are
expressed in arbitrary units. Co-expression of torsinA and 1-sarcoglycan
results in a highly significant (#P, 0.005) reduction in the levels of
1-sarcoglycan and the MDS-associated mutants, H36R/P and L172R. Pair-
wise comparison of the observed reduction in the levels of 1-sarcoglycan
and mutants when co-expressed with torsinA shows a statistically significant
(P, 0.05) difference on the steady-state levels of 1-sarcoglycan when
compared with the mutants. The error bars show the SEM from six indepen-
dent experiments.
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We also examined the effect of torsinA on the trafficking
of 1-sarcoglycan to the cell surface. Using conventional
chemiluminescence detection of proteins on western blots,
co-expression of wild-type torsinA and torsinADE304 with
1-sarcoglycan had no apparent effect upon 1-sarcoglycan
trafficking to the cell surface or the levels of the protein
(Fig. 8B). Furthermore, co-expression of torsinA and the
mutants H36P and L172R did not enhance trafficking of mutant
1-sarcoglycan to the plasma membrane. However, co-expression
of torsinA and the 1-sarcoglycan mutants H36P and L172R
caused a dramatic reduction in the steady-state levels of the
mutant proteins (Fig. 8B). To quantify the differential effect of
torsinAco-expression on the steady-state levels ofmutant relative
to the wild-type protein, quantitative two-colour immunoblotting
was used to determine protein levels relative to a-tubulin in
transfected HEK 293T cells. Co-expression of torsinA with
1-sarcoglycan and the MDS-associated mutants caused a statisti-
cally significant (P, 0.005) reduction in the steady-state levels
of each protein when compared with control groups where
1-sarcoglycan and the mutants were co-transfected with pCIneo
(Fig. 8C). However, torsinA expression caused a much greater
reduction in the levels of the three mutants compared with the
wild-type that was statistically significant (P, 0.05). While the
levels of the wild-type protein were reduced by 27% when
torsinA is co-expressed, the levels of H36P, H36R and L172R
were reduced by 58.3, 58.9 and 58.9%, respectively, when
co-expressed with torsinA (Fig. 8C). This effect is independent
of the total protein synthesized because the percentage change
is expressed relative to the levels of each protein in a pair-wise
comparison (e.g. wild-type 1-sarcoglycan compared with wild-
type 1-sarcoglycan and torsinA).
These data suggest that torsinA may augment the clearance
of 1-sarcoglycan from the cell and could indicate a role for
torsinA in the quality control of protein folding in the ER.
DISCUSSION
It is now well established that mutations in the gene encoding
the plasma membrane protein, 1-sarcoglycan cause MDS.
While genetics has been invaluable in determining the aetiol-
ogy of MDS, little is known about the function of
1-sarcoglycan in the central nervous system and its role in
the molecular pathology of MDS. In this study, we show
that three different single amino acid changes that cause
MDS produce proteins that are not targeted to the plasma
membrane and are degraded by the ubiquitin proteasome
system. We also show that torsinA can interact with the
MDS-associated 1-sarcoglycan mutants to augment their
removal from the cell possibly via the proteasome supporting
the suggestion made by others that torsinA, in common with
other members of the AAAþ protein family, may have intrin-
sic chaperone activity (45–47).
The correct folding of proteins in the secretory pathway is
essential for physiological delivery to the plasma membrane
or secretion (48). Human genetic diseases that affect proteins
that utilize the secretory pathway are frequently associated
with the intracellular retention and degradation of the mutant
protein. These diseases are diverse and include cystic fibrosis
(49), retinochisis (50), Robinow syndrome (51) and hereditary
emphysema (52). Herein, we show that missense mutations in
the SGCE gene produce proteins that are retained intracellu-
larly and degraded by the proteasome. Using FRAP and
PAGE, we provide complementary evidence that the L172R
mutant is probably misfolded. It has been shown that mis-
folded proteins can be locked into immobilized complexes
in the ER when cells are depleted of ATP (41). ATP is
required for the hydrolysis of disulphide bonds formed
between chaperones such as the PDIs and misfolded proteins
(53,54). Furthermore, misfolded proteins have a propensity
to form aggregates that can be resolved when separated by
native PAGE and can be cross-linked with different cross-
linkers including the thiol-selective homobifunctional
reagent, BMH (54). While L172R has the hallmarks of a
typical misfolded protein, the mutant H36P (and H36R) does
not appear to be processed by the cell in the same manner.
The H36P mutant was indistinguishable from the wild-type
protein by FRAP and was not immobilized by ATP depletion
(Fig. 7A). High molecular weight adducts were obtained by
native PAGE and BMH cross-linking (Fig. 7B) suggesting
that a proportion of H36P is bound to chaperones. However,
H36P was more rapidly degraded by the cell when compared
with the L172R mutant and had the highest level of polyubi-
quitination (Figs 4C and 5). These data could suggest that
the cell processes the two mutants differently and that the
H36P mutant may be too labile to form stable complexes
with chaperones.
Many of the disease-associated mutations in the SGCE gene
are nonsense mutations that cause the premature termination
of the protein. The most common MDS-associated nonsense
mutation in the SGCE gene is R102X that has been described
in at least nine different individuals (see http://www.dmd.nl/
sgce_seqvar.html (55). This mutation truncates 1-sarcoglycan
before the transmembrane domain and produces low levels of
protein possibly through nonsense-mediated decay of the
mutant transcript (Waite and Blake, unpublished data). The
overwhelming majority of MDS-associated mutations are
found in the extracellular part of the molecule. The extracellular
region of 1-sarcoglycan contains an N-linked glycosylation site
and several conserved cysteine residues that are likely to form
intramolecular disulphide bonds. Glycosylation and disulphide
bond formation are initiated in the lumen of the ER and rep-
resent major quality control checkpoints for proteins in the
secretory pathway. We have found that co-expression of the
MDS-associated mutants with wild-type 1-sarcoglycan does
not prevent trafficking of the wild-type protein to the cell
surface and therefore precludes a dominant gain-of-function
role for the mutant in plasma membrane delivery. From the
data presented in this article, we conclude that MDS is probably
caused by the loss of 1-sarcoglycan function at the plasma mem-
brane. Importantly, 1-sarcoglycan (and torsinA) is expressed in a
wide range of tissues, yet the primary defect in the dystonias
appears to reside within neurons of the basal ganglia and/or cer-
ebellum (43). Furthermore, MDS patients with SGCE mutations
do not show any signs of muscle disease. It is therefore concei-
vable that, in this context, 1-sarcoglycan may co-operate with
other membrane proteins to modulate the activity of neurons
in the basal ganglia and cerebellum.
A mutation in the d-sarcoglycan gene, S151A, has been
reported to cause autosomal dominant cardiomyopathy (56).
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Furthermore, a secondmutation, N211Y, found in a family with
mild proximal myopathy also appears to be dominantly inher-
ited (57). Each of these amino acids is located in the extracellu-
lar domain of d-sarcoglycan. It is possible that these diseases are
dominantly inherited because the wild-type protein could traffic
the altered protein to themembrane (Fig. 6B). This could disrupt
the assembly and function of the muscle-expressed sarcoglycan
complex leading to a disease state. It is also noteworthy that an
extracellular deletion of g-sarcoglycan is trafficked to sarco-
lemma but disrupts the function of the sarcoglycan complex
in a family with LGMD and cardiomyopathy (58). It is therefore
possible that mutations in individual sarcoglycans that can
by-pass the normal quality control pathway mechanism in the
secretory pathway could cause disease through a dominant
negative mechanism.
Intracellular trafficking has been postulated to play an import-
ant role in the molecular pathology of dystonia. The AAA(þ)
protein torsinA is found in the lumen of the ER and can regulate
the plasmamembrane delivery of some polytopicmembrane pro-
teins including the dopamine transporter (34,59). Co-expression
of torsinA and a number of polytopic proteins caused the intra-
cellular retention of the polytopic protein and reduced targeting
to the plasma membrane (34). Torres et al. (34) also showed
that co-expression of torsinADE302/303 and the wild-type
protein caused the sequestration of the wild-type protein into oli-
gomeric complexes that formed aggregates. Co-expression of
wild-type and mutant torsinA reversed the effect on polytopic
membrane protein trafficking presumably through a dominant-
negative effect (34). In this study, we have found that torsinA
reduces the levels of both wild-type and mutant sarcoglycan
when co-expressed in vitro. The extent of this effect is dependent
upon protein conformation, such that torsinA expression reduces
steady-state levels of the 1-sarcoglycan mutants by 60% com-
pared with the wild-type control that is only reduced by 30%.
Thus, torsinA could co-operate with the proteasome to augment
the clearance ofmisfolded proteins from the cell. This hypothesis
is supported by a study inCaenorhabditis eleganswhich showed
that torsinA suppresses polyglutamine-induced protein aggrega-
tion (46). Caldwell et al. found that the C. elegans orthologue of
torsinA and ubiquitin were targeted to the sites of protein aggre-
gation (46). Finally, many members of the AAA(þ) protein
family have been shown to have chaperone functions related to
their ATP-dependent ability to unfold proteins during degra-
dation [see (60) for recent review]. It should be noted that
torsinA has also been shown to play an important role in
maintaining the integrity of the nuclear envelope (61–63). Fur-
thermore, protein aggregates produced by transfection of
torsinA mutants may be dependent upon expression levels
because cells expressing low levels ofmutant torsinA show a dis-
tinct perinuclear (nuclear envelope) staining pattern, whereas
aggregates predominate in cells expressing high levels of the
mutant (62,63).
In conclusion, we have shown that MDS-associated mis-
sense mutations in the extracellular region of 1-sarcoglycan
impair trafficking to the plasma membrane. The mutant pro-
teins are retained intracellularly, show evidence of misfolding
and are degraded by the ubiquitin proteasome system.
Co-expression of torsinA appears to reduce the steady-state
levels of mutant 1-sarcoglycan but has little effect on the wild-
type protein.
MATERIALS AND METHODS
Antibodies
The anti-1-sarcoglycan antibody, esg-5009, was raised in
rabbits immunized with a thioredoxin fusion protein containing
the last 98 amino acids of mouse 1-sarcoglycan. The antisera
was purified by affinity chromatography using the antigen
coupled to Sulfolink (Pierce, Rockford, IL, USA) as described
previously (64). Biotinylated esg-5009 was prepared by react-
ing 1 mg of affinity-purified antibody with sulfo-NHS-LC-
biotin following the manufacturer’s instructions (Pierce).
Commercial antibodies were purchased from BD Bioscience
(GM130), Stressgen, San Diego, CA, USA (PDI), Covance
Research Products, Berkley, CA, USA (HA.11 anti-HA and
B34, anti-GFP), Novocastra Laboratories Ltd, Newcastle-
Upon-Tyne, UK (a-sarcoglycan, NCL-a-SARC; b-sarcoglycan,
NCL-b-SARC and b-dystroglycan, 43DAG 8D5 monoclonal
antibodies), Rockland Immunochemicals, PA, USA (IRDye
TM
800 anti-mouse IgG), Invitrogen (Alexa Fluor 488, 568 and
680) and Sigma (a-tubulin). The anti c-myc monoclonal anti-
body 9E10, was produced in-house from a hybridoma and
was purified and concentrated by protein G-sepharose chrom-
atography (GE Healthcare). The anti-dystrophin 2166 and anti-
dystrobrevin bCT-FP were produced in-house and are described
elsewhere (40,65).
Expression constructs and site-directed mutagenesis
Mouse 1-sarcoglycan was amplified from a brain cDNA
library by PCR using the primers esg-SalI (50-CGCG
TCGACCTTGGACGGGAAAGGGTCG) and esg-NotI
(50-CGCGCGGCCGCTCAGGGATACCATTTACCTGTAG).
The PCR product was digested and cloned into the SalI/
NotI sites of pCIneo (Promega). EYFP-tagged 1-sarcoglycan
and mutants thereof were produced by PCR with
the primers, 50-CGGAAGCTTCTCAAGATGAGCCCCGCG
and 50-CCGGGATCCCGGGGATACCATTTACCTGTAGT,
digested with HindIII and BamHI and subcloned into the cor-
responding sites in pEYFP-N1 (Clontech). The QuickChange
site-directed mutagenesis kit (Stratagene) was used to intro-
duce point mutations in the SGCE cDNA. The mutagenic
primers are shown below with mutated codons italicized.
L172Rf, 50-CAGCCAGAGCGCCGCAACGCCATAAACAT;
L172Rr, 50-ATGTTTATGGCGTTGCGGCGCTCTGGCTG;
H36Pf, 50-CAGGTGTCCTCTTTGTTCCGGTGTTGGAGA
GAGAGTA; H36Pr, 50-TACTCTCTCTCCAACACCGGAA
CAAAGAGGACACCTG; H36Rf, 50-AGGTGTCCTCTTT
GTTAGAGTGTTGGAGAGAGAG; H36Rr, 50-CTCTCTCT
CCAACACTCTAACAAAGAGGACACCT. A torsinA con-
struct with a C-terminal myc-tag (torsinA-myc) was generated
by PCR using the primers, 50-CGGGAATTCGGGTCCGGTT
ATGAAGCT and 50-CGCGTCGACTCACAAGTCCTCTT
CAGAAATGAGCTTTTGCTCGTCATCCAGGTAGTAGT
CCA. The PCR product was digested with EcoRI and SalI and
cloned into the corresponding sites in pCIneo (Promega). T
orsinADE304 was made by site-directed mutagenesis using
the primers, DYT1DE304-F, 50-CAGCAAGGTAGCGGAAA
TGACGTTCTTCCCC and DYTDE304-R, 50-GGGGAA
GAACGTCATTTCCGCTACCTTGCTG. The mouse a-sar-
coglycan (aSG-EYFP) construct with a C- terminal EYFP
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fusion was generated using the primers, 50-TATGAA
TTCTGATGGCAGCAGCAGTAACTTGG and 50-ACCGT
CGACTGGTGCTGGTCCAGGATAAGAG. The PCR product
was digested with EcoRI and SalI and cloned into the corre-
sponding sites in pEYFP-N1. The mutant H77C-EYFP was gen-
erated by site-directed mutagenesis using the primers H77Cf
50-GCCCAGGTGGCTGTGCTACACACAGCGCAG and
H77Cr 50-CTGCGCTGTGTGTAGCACAGCCACCTGGGC.
All constructs were verified by sequencing. Human a-, b- and
1-sarcoglycan cDNA clones were purchased from OriGene
Technologies Inc. (Rockville, MD, USA). All constructs were
verified by sequencing. The HA-ubiquitin plasmid pMT123
was kindly provided by Professor Dirk Bohmann, University
of Rochester Medical Center (66).
Cell culture, transfection and drug treatment
COS-7 and HEK 293T were grown in Dulbecco’s modified
Eagle’s medium (DMEM) supplemented with Glutamax, 10%
fetal calf serum (FCS) and penicillin/streptomycin. Cells
grown in six-well plates with and without coverslips were trans-
fected with 1 mg of each expression construct using Fugene 6
reagent (Roche) according to the manufacturer’s instructions.
SH-SY5Y human neuroblastoma cells were cultured in F-12
(Ham)/DMEM (1:1) supplemented with Glutamax, 15% FCS
and penicillin/streptomycin. Neuroblastomas were grown in
six-well plates with coverslips and transfected with 4 mg of
each expression construct using Lipofectamine 2000 (Invitro-
gen) according to the manufacturer’s instructions. The protea-
some inhibitors, lactacystin (10mM, Sigma) and MG132
(50mM, Sigma) were applied to the cells 24 h after transfection
as described previously (37). Cells were incubated with the
drugs for 16–24 h and were then processed as described
below. Hippocampal and cortical neuronal cultures were pre-
pared from 18-day-old embryonic rats and grown on coverslips
in 24-well-plates or in 6-well-plates as described previously
(67). Briefly, pregnant rats were decapitated, the embryos
removed and the cortices or hippocampi dissected followed
by trypsinization and trituration to dissociate the cells.
Neurons were then plated on poly-D-lysine coated coverslips
at a density of 15 000 cells/cm2 for immunocytochemistry.
Neurons were initially maintained in DMEM containing 10%
FCS, 1 antibiotic/antimycotic (Life Technologies) and 2 mM
glutamine. From the second day, hippocampal neurons were
maintained in neurobasal medium containing B12 supplement,
1 antibiotic/antimycotic and 0.5 mM glutamine. Cortical
neurons were grown in neurobasal media containing 2%
B27, 0.5 mM L-glutamine, 25 mM glutamate, 0.05% gentamicin.
To restrict the proliferation of non-neuronal cells, after 4
days the media were changed to neurobasal media sup-
plemented with 2% B27, 0.5 mM L-glutamine, 3 mM cytosine
b-D-arabinofuranoside and 0.05% gentamicin. Cortical
neurons were transfected at 7 d.i.v with 4 mg of each expression
construct using Lipofectamine 2000 (Invitrogen).
Immunocytochemistry and confocal microscopy
For immunocytochemistry, neurons were rinsed in phosphate-
buffered saline (PBS) after removal of cell culture media
and directly post-fixed in 4% (w/v) paraformaldehyde for
15–20 min at room temperature. The fixed cells were
washed twice with 25 mM glycine in PBS and then blocked
with 10% (v/v) horse serum, 3% (w/v) bovine serum
albumin (BSA) and 0.2% (v/v) Triton X-100 in PBS (blocking
solution) for 1 h. For immunostaining, cells were incubated
overnight at 48C with primary antibody diluted in blocking
solution. After careful rinsing in PBS, cultures were incubated
with the secondary antibody (Alexa Fluor 488 or 568 conju-
gates) diluted in blocking solution without Triton X-100 for
1 h at room temperature. Cells were washed with PBS
and mounted in Vectashield (Vector Laboratories). The
stained cells were visualized using a Nikon Eclipse TE300
inverted microscope equipped with a Hamamatsu digital
camera and images visualized using Simple PCI (Digital
Pixel) software. A similar protocol was used for immunostain-
ing of COS-7 and SH-SY5Y cells, however, fixation was per-
formed in methanol (2208C) to preserve the structure of the
ER when the anti-PDI antibody was used.
Fluorescent recovery after photobleaching
COS-7 cells were grown on cover slips and transfected with
either EYFP-tagged 1-sarcoglycan, H36P-EYFP or
L172R-EYFP. Twenty-four hours after transfection, cells
were washed with HEPES buffered Hank’s buffered salt
solution (HBSS) containing 0.33 mM D-glucose. Wild-type
1-sarcoglycan was treated with 1 mM brefeldin-A for 1 h
before use, to ensure that the majority of protein was retained
in the ER, and brefeldin-A was added to the HBSS for the dur-
ation of the FRAP experiments. ATP depletion of the cells was
carried out using 2-deoxyglucose and 0.02% sodium azide
treatment of the cells for 30 min, as described by Nehls
et al. (41) in glucose-free HBSS and the FRAP experiments
were performed at 308C. Preliminary experiments showed
that the effect of 2-deoxyglucose treatment of the cells was
dose-dependent and the lowest effective concentration was
found to be 0.5 mM, and this was used throughout the exper-
iments. ATP depleted cells were not harmed by the treatment,
as they showed full FRAP recovery if replaced into tissue
culture medium for 1 h after the experiments were completed.
Photo bleaching was carried out using the 514 nm argon laser
line of an LSM 510 Zeiss confocal microscope at 75% of full
power equivalent to 17 mW, recovery was monitored at 1% of
this laser output. The bleached regions of interest were gener-
ally 50 pixels in diameter and seven iterations were performed
to bleach the region. Unbleached regions of the same cell were
used to control for photobleaching during the recovery period,
though this was generally minimal. For statistical analysis, the
recovery curve for each cell was fitted to the equation for dif-
fusion rates and mobile fractions as described in (68) using
Graphpad Prism 4 software. The differences in the calculated
diffusion rates and fractional recoveries were analyzed using
the same software and the Mann–Whitney t-test.
Western blotting
Western blots were performed as described previously (64).
Samples were prepared for native SDS–PAGE in native
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PAGE buffer (1, 67 mM Tris–HCl pH 6.8, 2% (w/v) SDS,
10% (v/v) glycerol, 10 mM iodoacetamide). For quantitative,
two-colour western blot analysis, protein extracts were
separated by SDS–PAGE and electroblotted onto nitrocellu-
lose membranes before incubation with the esg-5009 polyclo-
nal antibody and a mouse monoclonal anti-a-tubulin antibody.
After washing, the membranes were incubated with IR
fluorophore-conjugated secondary antibodies, IRDye
TM
800
anti-mouse IgG and Alexa Fluor 680 anti-rabbit IgG. Mem-
branes were then washed with Tris-buffered saline (TBS) con-
taining 0.1% (v/v) Tween20 and rinsed in TBS. Simultaneous
two-colour detection was performed using an Odyssey infra-
red imaging system (LI-COR Biosciences, Lincoln, NE,
USA). Quantification of 1-sarcoglycan was performed using
the Odysseyw imager application v1.2, normalized to
a-tubulin fluorescence as an internal reference. Two-tailed
Student’s t-tests were used for the statistical analysis of
protein levels.
Immunoprecipitation
Immunoprecipitations from heterologous cells were performed
using either anti-c-myc 9E10 monoclonal antibody conjugated
to protein G-sepharose beads or esg-5009 conjugated protein
G-sepharose beads. The antibodies were covalently cross-
linked to protein G-sepharose using dimethyl pimelimidate
as described previously (69). Transfected HEK 293T cells
were washed once with PBS and lysed and solubilized in
RIPA buffer (150 mM NaCl, 50 mM Tris pH 8.0, 1% (v/v)
Triton X-100, 0.5% (w/v) deoxycholate, 1 mM EGTA) at
48C for 30 min. Cell debris was removed by centrifugation.
Lysates were precleared with unconjugated protein G-
sepharose at 48C for 1 h. For immunoprecipitation, the
lysates were mixed with the antibody-protein G-sepharose
beads for 3 h at 48C, after which the beads were washed
three times with RIPA buffer. The immunoprecipitated pro-
teins were eluted from the beads by boiling in SDS–PAGE
sample buffer for 5 min. 1-Sarcoglycan was immunoprecipi-
tated from whole mouse brain RIPA extracts (1 g in 20 ml)
using 4 mg of esg-5009 as described previously (40).
Glycosidase treatment
For glycosidase treatment of endogenous 1-sarcoglycan,
mouse brains from eight-week old male CD1 mice were
homogenized in RIPA buffer containing 0.1% SDS (w/v)
and incubated at 48C for 30 min. Lysates were clarified by
centrifugation at 100 000g for 30 min. The brain lysate was
precleared with protein G-sepharose at 48C for 3 h followed
by incubation with esg-5009 (10 mg) for 5 h at 48C. After
overnight incubation at 48C, immune complexes were cap-
tured with goat anti-rabbit IgG-Magnabind beads (Pierce)
and washed four times with RIPA buffer. Brain-derived
1-sarcoglycan was resuspended directly in the appropriate
glycosidase buffer. Endoglycosidase (Endo) H and peptide
N-glycosidase (PNGase) F were purchased from New
England Biolabs and were used as described previously (37).
Glycosidase treatment on proteins produced in transfected
cells was performed as described previously (37).
Ubiquitination assays
HEK 293T cells were transfected singly with wild-type
1-sarcoglycan and the MDS mutants, and in combination
with HA-ubiquitin. The proteasome inhibitors lactacystin
(10 mM) or MG132 (50 mM) were applied to cells 24 h after
transfection and incubated for a further 16 h. Transfected
cells were washed once with PBS and solubilized in lysis
buffer (100 mM Tris pH 8.0, 0.5% (w/v) SDS, 5 mM DTT).
Lysates were briefly sonicated, boiled for 5 min and cooled
on ice. A sample of each lysate was retained before diluting
the sample 1:10 with RIPA buffer. 1-Sarcoglycan was immu-
noprecipitated with 4 mg of esg-5009 for 5 h at 48C. Immune
complexes were captured with goat anti-rabbit IgG Magnabind
beads (Pierce) at 48C overnight. Immunoprecipitated proteins
were washed three times with RIPA buffer and eluted by
boiling for 5 min in SDS–PAGE sample buffer.
BMH cross-linking
Transfected COS-7 cells were lysed in PBS containing 1%
(v/v) Triton X-100 in the presence of the cross-linker BMH
(Pierce) at a final concentration of 1 mM. The reaction was
incubated for 30 min at room temperature before quenching
by the addition of an equal volume of 2 SDS–PAGE
sample buffer containing DTT to a final concentration of
20 mM.
Cell surface biotinylation
Transfected COS-7 and HEK 293T cells were washed three
times with ice-cold PBS and incubated for 30 min at 48C
with gentle agitation in the presence of the membrane
impermeable sulfo-NHS-biotin reagent (Pierce) prepared in
PBS (1 mg/ml); 1 ml of reagent was used per well on a
6-well plate. The cells were then washed for 10 min at room
temperature with 100 mM glycine prepared in PBS to
quench the cross-linker and remove excess biotin. Cells
were rinsed in PBS and lysed in RIPA buffer. 1-Sarcoglycan
was immunoprecipitated from the biotin-labelled cells using
esg-5009 conjugated protein G-sepharose beads. Samples
were separated by SDS–PAGE and western blotted with the
esg-5009 or horseradish peroxidase–streptavidin (GE Health-
care).
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG Online.
ACKNOWLEDGEMENTS
The authors thank other members of the laboratory for helpful
comments on this manuscript and Professor Dirk Bohmann for
kindly supplying the plasmid encoding HA-ubiquitin. These
studies were supported by grants from the Wellcome Trust
and Oriel College, Oxford (Isobel Laing Fellowship to
D.J.B.). D.J.B. is a Wellcome Trust Senior Fellow. A.W. is
supported by an MRC studentship. M.L. is supported by the
Usher Cunningham Fellowship at Exeter College. R.V.S.
was a recipient of a fellowship from the Alberta Heritage
340 Human Molecular Genetics, 2007, Vol. 16, No. 3
 at A
cquisitions on A
pril 11, 2012
http://hm
g.oxfordjournals.org/
D
ow
nloaded from
 
Foundation for Medical Research. Funding to pay the Open
Access Publication charges for this article was provided by
the Wellcome Trust.
Conflict of Interest statement. There are no conflicts of interest
associated with this work.
REFERENCES
1. Blake, D.J., Weir, A., Newey, S.E. and Davies, K.E. (2002) Function and
genetics of dystrophin and dystrophin-related proteins in muscle. Physiol.
Rev., 82, 291–329.
2. Yoshida, M., Suzuki, A., Yamamoto, H., Noguchi, S., Mizuno, Y. and
Ozawa, E. (1994) Dissociation of the complex of dystrophin and its
associated proteins into several unique groups by n-octyl
beta-D-glucoside. Eur. J. Biochem., 222, 1055–1061.
3. Chan, Y.M., Bonnemann, C.G., Lidov, H.G. and Kunkel, L.M. (1998)
Molecular organization of sarcoglycan complex in mouse myotubes in
culture. J. Cell Biol., 143, 2033–2044.
4. Holt, K.H. and Campbell, K.P. (1998) Assembly of the sarcoglycan
complex. Insights for muscular dystrophy. J. Biol. Chem., 273,
34667–34670.
5. Vainzof, M., Passos-Bueno, M.R., Canovas, M., Moreira, E.S., Pavanello,
R.C., Marie, S.K., Anderson, L.V., Bonnemann, C.G., McNally, E.M.,
Nigro, V. et al. (1996) The sarcoglycan complex in the six autosomal
recessive limb-girdle muscular dystrophies. Hum. Mol. Genet., 5,
1963–1969.
6. Nishiyama, A., Endo, T., Takeda, S. and Imamura, M. (2004)
Identification and characterization of epsilon-sarcoglycans in the central
nervous system. Brain Res. Mol. Brain Res., 125, 1–12.
7. Ettinger, A.J., Feng, G. and Sanes, J.R. (1997) 1-Sarcoglycan, a broadly
expressed homologue of the gene mutated in limb-girdle muscular
dystrophy 2D [published erratum appears in J. Biol. Chem. (1998) 273,
19922]. J. Biol. Chem., 272, 32534–32538.
8. Xiao, J. and LeDoux, M.S. (2003) Cloning, developmental regulation and
neural localization of rat epsilon-sarcoglycan. Brain Res. Mol. Brain Res.,
119, 132–143.
9. McNally, E.M., Ly, C.T. and Kunkel, L.M. (1998) Human
epsilon-sarcoglycan is highly related to alpha-sarcoglycan (adhalin), the
limb girdle muscular dystrophy 2D gene. FEBS Lett., 422, 27–32.
10. Liu, L.A. and Engvall, E. (1999) Sarcoglycan isoforms in skeletal muscle.
J. Biol. Chem., 274, 38171–38176.
11. Straub, V., Ettinger, A.J., Durbeej, M., Venzke, D.P., Cutshall, S., Sanes,
J.R. and Campbell, K.P. (1999) 1-Sarcoglycan replaces alpha-sarcoglycan
in smooth muscle to form a unique dystrophin–glycoprotein complex.
J. Biol. Chem., 274, 27989–27996.
12. Imamura, M., Araishi, K., Noguchi, S. and Ozawa, E. (2000) A
sarcoglycan-dystroglycan complex anchors Dp116 and utrophin in the
peripheral nervous system. Hum. Mol. Genet., 9, 3091–3100.
13. Chan, P., Gonzalez-Maeso, J., Ruf, F., Bishop, D.F., Hof, P.R. and
Sealfon, S.C. (2005) Epsilon-sarcoglycan immunoreactivity and mRNA
expression in mouse brain. J. Comp. Neurol., 482, 50–73.
14. Hack, A.A., Groh, M.E. and McNally, E.M. (2000) Sarcoglycans in
muscular dystrophy. Microsc. Res. Technol., 48, 167–180.
15. Wheeler, M.T., Zarnegar, S. and McNally, E.M. (2002) Zeta-sarcoglycan,
a novel component of the sarcoglycan complex, is reduced in muscular
dystrophy. Hum. Mol. Genet., 11, 2147–2154.
16. Shiga, K., Yoshioka, H., Matsumiya, T., Kimura, I., Takeda, S. and
Imamura, M. (2006) Zeta-sarcoglycan is a functional homologue of
gamma-sarcoglycan in the formation of the sarcoglycan complex. Exp.
Cell Res., 312, 2083–2092.
17. Grabowski, M., Zimprich, A., Lorenz-Depiereux, B., Kalscheuer, V.,
Asmus, F., Gasser, T., Meitinger, T. and Strom, T.M. (2003) The
epsilon-sarcoglycan gene (SGCE), mutated in myoclonus-dystonia
syndrome, is maternally imprinted. Eur. J. Hum. Genet., 11, 138–144.
18. Hedrich, K., Meyer, E.M., Schule, B., Kock, N., de Carvalho Aguiar, P.,
Wiegers, K., Koelman, J.H., Garrels, J., Durr, R., Liu, L. et al. (2004)
Myoclonus-dystonia: detection of novel, recurrent, and de novo SGCE
mutations. Neurology, 62, 1229–1231.
19. Zimprich, A., Grabowski, M., Asmus, F., Naumann, M., Berg, D., Bertram,
M., Scheidtmann, K., Kern, P., Winkelmann, J., Muller-Myhsok, B. et al.
(2001) Mutations in the gene encoding epsilon-sarcoglycan cause
myoclonus-dystonia syndrome. Nat. Genet., 29, 66–69.
20. Mahloudji, M. and Pikielny, R.T. (1967) Hereditary essential myoclonus.
Brain, 90, 669–674.
21. Nemeth, A.H. (2002) The genetics of primary dystonias and related
disorders. Brain, 125, 695–721.
22. Bressman, S.B. (2003) Dystonia: phenotypes and genotypes. Rev. Neurol.
(Paris), 159, 849–856.
23. Muller, B., Hedrich, K., Kock, N., Dragasevic, N., Svetel, M., Garrels, J.,
Landt, O., Nitschke, M., Pramstaller, P.P., Reik, W. et al. (2002) Evidence
that paternal expression of the epsilon-sarcoglycan gene accounts for
reduced penetrance in myoclonus-dystonia. Am. J. Hum. Genet., 71,
1303–1311.
24. Piras, G., El Kharroubi, A., Kozlov, S., Escalante-Alcalde, D., Hernandez,
L., Copeland, N.G., Gilbert, D.J., Jenkins, N.A. and Stewart, C.L. (2000)
Zac1 (Lot1), a potential tumor suppressor gene, and the gene for
epsilon-sarcoglycan are maternally imprinted genes: identification by a
subtractive screen of novel uniparental fibroblast lines. Mol. Cell. Biol.,
20, 3308–3315.
25. Yokoi, F., Dang, M.T., Mitsui, S. and Li, Y. (2005) Exclusive paternal
expression and novel alternatively spliced variants of epsilon-sarcoglycan
mRNA in mouse brain. FEBS Lett., 579, 4822–4828.
26. de Carvalho Aguiar, P., Sweadner, K.J., Penniston, J.T., Zaremba, J., Liu,
L., Caton, M., Linazasoro, G., Borg, M., Tijssen, M.A., Bressman, S.B.
et al. (2004) Mutations in the Naþ/Kþ-ATPase alpha3 gene ATP1A3 are
associated with rapid-onset dystonia parkinsonism. Neuron, 43, 169–175.
27. Marechal, L., Raux, G., Dumanchin, C., Lefebvre, G., Deslandre, E.,
Girard, C., Campion, D., Parain, D., Frebourg, T. and Hannequin, D.
(2003) Severe myoclonus-dystonia syndrome associated with a novel
epsilon-sarcoglycan gene truncating mutation. Am. J. Med. Genet., 119B,
114–117.
28. Tezenas du Montcel, S., Clot, F., Vidailhet, M., Roze, E., Damier, P.,
Jedynak, C.P., Camuzat, A., Lagueny, A., Vercueil, L., Doummar, D.
et al. (2006) Epsilon sarcoglycan mutations and phenotype in French
patients with myoclonic syndromes. J. Med. Genet, 43, 394–400.
29. Valente, E.M., Edwards, M.J., Mir, P., DiGiorgio, A., Salvi, S., Davis, M.,
Russo, N., Bozi, M., Kim, H.T., Pennisi, G. et al. (2005) The
epsilon-sarcoglycan gene in myoclonic syndromes. Neurology, 64,
737–739.
30. Schule, B., Kock, N., Svetel, M., Dragasevic, N., Hedrich, K., De
Carvalho Aguiar, P., Liu, L., Kabakci, K., Garrels, J., Meyer, E.M. et al.
(2004) Genetic heterogeneity in ten families with myoclonus-dystonia.
J. Neurol. Neurosurg. Psychiatry, 75, 1181–1185.
31. Dickens, N.J., Beatson, S. and Ponting, C.P. (2002) Cadherin-like
domains in alpha-dystroglycan, alpha/epsilon-sarcoglycan and yeast and
bacterial proteins. Curr. Biol., 12, R197–R199.
32. Yokoi, F., Dang, M.T., Li, J. and Li, Y. (2006) Myoclonus, motor deficits,
alterations in emotional responses and monoamine metabolism in
epsilon-sarcoglycan deficient mice. J. Biochem. (Tokyo), 140, 141–146.
33. Goodchild, R.E. and Dauer, W.T. (2005) The AAAþ protein torsinA
interacts with a conserved domain present in LAP1 and a novel ER
protein. J. Cell Biol., 168, 855–862.
34. Torres, G.E., Sweeney, A.L., Beaulieu, J.M., Shashidharan, P. and Caron,
M.G. (2004) Effect of torsinA on membrane proteins reveals a loss of
function and a dominant-negative phenotype of the dystonia-associated
DeltaE-torsinA mutant. Proc. Natl Acad. Sci. USA, 101, 15650–15655.
35. Kamm, C., Boston, H., Hewett, J., Wilbur, J., Corey, D.P., Hanson, P.I.,
Ramesh, V. and Breakefield, X.O. (2004) The early onset dystonia protein
torsinA interacts with kinesin light chain 1. J. Biol. Chem., 279,
19882–19892.
36. Misbahuddin, A., Placzek, M.R., Taanman, J.W., Gschmeissner, S.,
Schiavo, G., Cooper, J.M. and Warner, T.T. (2005) Mutant torsinA, which
causes early-onset primary torsion dystonia, is redistributed to
membranous structures enriched in vesicular monoamine transporter in
cultured human SH-SY5Y cells. Mov. Disord., 20, 432–440.
37. Esapa, C.T., Bentham, G.R., Schroder, J.E., Kroger, S. and Blake, D.J.
(2003) The effects of post-translational processing on dystroglycan
synthesis and trafficking. FEBS Lett., 555, 209–216.
38. Draviam, R.A., Wang, B., Li, J., Xiao, X. and Watkins, S.C. (2006)
Mini-dystrophin efficiently incorporates into the dystrophin protein
complex in living cells. J. Muscle Res. Cell Motil., 27, 53–67.
Human Molecular Genetics, 2007, Vol. 16, No. 3 341
 at A
cquisitions on A
pril 11, 2012
http://hm
g.oxfordjournals.org/
D
ow
nloaded from
 
39. Shi, W., Chen, Z., Schottenfeld, J., Stahl, R.C., Kunkel, L.M. and Chan,
Y.M. (2004) Specific assembly pathway of sarcoglycans is dependent on
beta- and delta-sarcoglycan. Muscle Nerve, 29, 409–419.
40. Blake, D.J., Hawkes, R., Benson, M.A. and Beesley, P.W. (1999)
Different dystrophin-like complexes are expressed in neurons and glia.
J. Cell Biol., 147, 645–658.
41. Nehls, S., Snapp, E.L., Cole, N.B., Zaal, K.J., Kenworthy, A.K., Roberts,
T.H., Ellenberg, J., Presley, J.F., Siggia, E. and Lippincott-Schwartz, J.
(2000) Dynamics and retention of misfolded proteins in native ER
membranes. Nat. Cell Biol., 2, 288–295.
42. Klein, C., Liu, L., Doheny, D., Kock, N., Muller, B., de Carvalho Aguiar,
P., Leung, J., de Leon, D., Bressman, S.B., Silverman, J. et al. (2002)
Epsilon-sarcoglycan mutations found in combination with other dystonia
gene mutations. Ann. Neurol., 52, 675–679.
43. Ozelius, L.J., Hewett, J.W., Page, C.E., Bressman, S.B., Kramer, P.L.,
Shalish, C., de Leon, D., Brin, M.F., Raymond, D., Corey, D.P. et al.
(1997) The early-onset torsion dystonia gene (DYT1) encodes an
ATP-binding protein. Nat. Genet., 17, 40–48.
44. Draviam, R.A., Wang, B., Shand, S.H., Xiao, X. and Watkins, S.C. (2006)
Alpha-sarcoglycan is recycled from the plasma membrane in the absence
of sarcoglycan complex assembly. Traffic, 7, 793–810.
45. Vale, R.D. (2000) AAA proteins. Lords of the ring. J. Cell Biol., 150,
F13–F19.
46. Caldwell, G.A., Cao, S., Sexton, E.G., Gelwix, C.C., Bevel, J.P. and
Caldwell, K.A. (2003) Suppression of polyglutamine-induced protein
aggregation in Caenorhabditis elegans by torsin proteins. Hum. Mol.
Genet., 12, 307–319.
47. Cao, S., Gelwix, C.C., Caldwell, K.A. and Caldwell, G.A. (2005)
Torsin-mediated protection from cellular stress in the dopaminergic
neurons of Caenorhabditis elegans. J. Neurosci., 25, 3801–3812.
48. Ellgaard, L. and Helenius, A. (2003) Quality control in the endoplasmic
reticulum. Nat. Rev. Mol. Cell Biol., 4, 181–191.
49. Cheng, S.H., Gregory, R.J., Marshall, J., Paul, S., Souza, D.W., White,
G.A., O’Riordan, C.R. and Smith, A.E. (1990) Defective intracellular
transport and processing of CFTR is the molecular basis of most cystic
fibrosis. Cell, 63, 827–834.
50. Wang, T., Waters, C.T., Rothman, A.M., Jakins, T.J., Romisch, K. and
Trump, D. (2002) Intracellular retention of mutant retinoschisin is the
pathological mechanism underlying X-linked retinoschisis. Hum. Mol.
Genet., 11, 3097–3105.
51. Chen, Y., Bellamy, W.P., Seabra, M.C., Field, M.C. and Ali, B.R. (2005)
ER-associated protein degradation is a common mechanism underpinning
numerous monogenic diseases including Robinow syndrome. Hum. Mol.
Genet., 14, 2559–2569.
52. Qu, D., Teckman, J.H., Omura, S. and Perlmutter, D.H. (1996)
Degradation of a mutant secretory protein, alpha1-antitrypsin Z, in the
endoplasmic reticulum requires proteasome activity. J. Biol. Chem., 271,
22791–22795.
53. Haggie, P.M., Stanton, B.A. and Verkman, A.S. (2002) Diffusional
mobility of the cystic fibrosis transmembrane conductance regulator
mutant, delta F508-CFTR, in the endoplasmic reticulum measured by
photobleaching of GFP-CFTR chimeras. J. Biol. Chem., 277,
16419–16425.
54. Tatu, U. and Helenius, A. (1997) Interactions between newly synthesized
glycoproteins, calnexin and a network of resident chaperones in the
endoplasmic reticulum. J. Cell. Biol., 136, 555–565.
55. Fokkema, I.F., den Dunnen, J.T. and Taschner, P.E. (2005) LOVD: easy
creation of a locus-specific sequence variation database using an
‘LSDB-in-a-box’ approach. Hum. Mutat., 26, 63–68.
56. Tsubata, S., Bowles, K.R., Vatta, M., Zintz, C., Titus, J., Muhonen, L.,
Bowles, N.E. and Towbin, J.A. (2000) Mutations in the human
delta-sarcoglycan gene in familial and sporadic dilated cardiomyopathy.
J. Clin. Invest., 106, 655–662.
57. Nigro, V., Piluso, G., Belsito, A., Politano, L., Puca, A.A., Papparella, S.,
Rossi, E., Viglietto, G., Esposito, M.G., Abbondanza, C. et al. (1996)
Identification of a novel sarcoglycan gene at 5q33 encoding a
sarcolemmal 35 kDa glycoprotein. Hum. Mol. Genet., 5, 1179–1186.
58. Crosbie, R.H., Lim, L.E., Moore, S.A., Hirano, M., Hays, A.P., Maybaum,
S.W., Collin, H., Dovico, S.A., Stolle, C.A., Fardeau, M. et al. (2000)
Molecular and genetic characterization of sarcospan: insights into
sarcoglycan-sarcospan interactions. Hum. Mol. Genet., 9, 2019–2027.
59. Kustedjo, K., Bracey, M.H. and Cravatt, B.F. (2000) Torsin A and its
torsion dystonia-associated mutant forms are lumenal glycoproteins that
exhibit distinct subcellular localizations. J. Biol. Chem., 275,
27933–27939.
60. Sauer, R.T., Bolon, D.N., Burton, B.M., Burton, R.E., Flynn, J.M., Grant,
R.A., Hersch, G.L., Joshi, S.A., Kenniston, J.A., Levchenko, I. et al.
(2004) Sculpting the proteome with AAA(þ) proteases and disassembly
machines. Cell, 119, 9–18.
61. Bragg, D.C., Camp, S.M., Kaufman, C.A., Wilbur, J.D., Boston, H.,
Schuback, D.E., Hanson, P.I., Sena-Esteves, M. and Breakefield, X.O.
(2004) Perinuclear biogenesis of mutant torsin-A inclusions in cultured
cells infected with tetracycline-regulated herpes simplex virus type 1
amplicon vectors. Neuroscience, 125, 651–661.
62. Gonzalez-Alegre, P. and Paulson, H.L. (2004) Aberrant cellular behavior
of mutant torsinA implicates nuclear envelope dysfunction in DYT1
dystonia. J. Neurosci., 24, 2593–2601.
63. Goodchild, R.E. and Dauer, W.T. (2004) Mislocalization to the nuclear
envelope: an effect of the dystonia-causing torsinA mutation. Proc. Natl
Acad. Sci. USA, 101, 847–852.
64. Benson, M.A., Newey, S.E., Martin-Rendon, E., Hawkes, R. and Blake,
D.J. (2001) Dysbindin, a novel coiled-coil-containing protein that
interacts with the dystrobrevins in muscle and brain. J. Biol. Chem., 276,
24232–24241.
65. Blake, D.J., Nawrotzki, R., Loh, N.Y., Gorecki, D.C. and Davies, K.E.
(1998) beta-dystrobrevin, a member of the dystrophin-related protein
family. Proc. Natl Acad. Sci. USA, 95, 241–246.
66. Treier, M., Staszewski, L.M. and Bohmann, D. (1994) Ubiquitin-
dependent c-Jun degradation in vivo is mediated by the delta domain. Cell,
78, 787–798.
67. Dresbach, T., Hempelmann, A., Spilker, C., tom Dieck, S., Altrock, W.D.,
Zuschratter, W., Garner, C.C. and Gundelfinger, E.D. (2003) Functional
regions of the presynaptic cytomatrix protein bassoon: significance for
synaptic targeting and cytomatrix anchoring. Mol. Cell Neurosci., 23,
279–291.
68. Barak, L.S., Ferguson, S.S., Zhang, J. and Caron, M.G. (1997) A
beta-arrestin/green fluorescent protein biosensor for detecting G
protein-coupled receptor activation. J. Biol. Chem., 272, 27497–27500.
69. Esapa, C.T., McIlhinney, R.A. and Blake, D.J. (2005) Fukutin-related
protein mutations that cause congenital muscular dystrophy result in
ER-retention of the mutant protein in cultured cells. Hum. Mol. Genet., 14,
295–305.
342 Human Molecular Genetics, 2007, Vol. 16, No. 3
 at A
cquisitions on A
pril 11, 2012
http://hm
g.oxfordjournals.org/
D
ow
nloaded from
 
